DNA viral infections complicating lung transplantation

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 3, 2013, Pages 380-404

  Clark, Ninam ^a   Lynch, Josephp ^b   Sayah, David ^b   Belperio, Johna ^b   Fishbein, Michaelc ^b   Weigt, S Samuel ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DNA viruses; lung transplantation; viral infection

Indexed keywords

ACICLOVIR; ARTESUNATE; BENZIMIDAVIR; CHICKENPOX VACCINE; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERLEUKIN 2; LEFLUNOMIDE; LETERMOVIR; MEFLOQUINE; MIRTAZAPINE; PREDNISONE; QUINOLONE DERIVATIVE; RAPAMYCIN; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE; VINCRISTINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BK VIRUS; BK VIRUS INFECTION; BLADDER IRRIGATION; CYTOMEGALOVIRUS INFECTION; DNA VIRUS; DNA VIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS INFECTION; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; JC VIRUS; KAPOSI SARCOMA; KIDNEY BIOPSY; LUNG TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NONHUMAN; PHARMACEUTICAL EQUIVALENCE; POLYOMAVIRUS INFECTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS DIAGNOSIS;

ANIMALS; ANTIVIRAL AGENTS; DNA VIRUS INFECTIONS; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879920144     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1348473     Document Type: Article

References (416)

1. Christie J. D., Edwards L. B., Kucheryavaya A. Y., et al. International Society of Heart and Lung Transplantation The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant: 2012; 31 10 1073 1086
2. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis: 1990; 12 07 S701 S710
3. Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ: 1973; 49 1 103 106
4. Söderberg-Nauclér C., Fish K. N., Nelson J. A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell: 1997; 91 1 119 126
5. Chou S. W. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med: 1986; 314 22 1418 1423
6. Lowance D., Neumayer H. H., Legendre C. M., et al. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med: 1999; 340 19 1462 1470
7. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis: 2002; 34 8 1094 1097
8. Gane E., Saliba F., Valdecasas G. J., et al. The Oral Ganciclovir International Transplantation Study Group Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet: 1997; 350 9093 1729 1733
9. Sagedal S., Hartmann A., Nordal K. P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int: 2004; 66 1 329 337
10. Linares L., Sanclemente G., Cervera C., et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc: 2011; 43 6 2145 2148
11. Humar A., Lebranchu Y., Vincenti F., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant: 2010; 10 5 1228 1237
12. Paya C., Humar A., Dominguez E., et al. Valganciclovir Solid Organ Transplant Study Group Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: 2004; 4 4 611 620
13. Humar A., Snydman D. AST Infectious Diseases Community of Practice Cytomegalovirus in solid organ transplant recipients. Am J Transplant: 2009; 9 04 S78 S86
14. Eid A. J., Arthurs S. K., Deziel P. J., Wilhelm M. P., Razonable R. R. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant: 2008; 22 2 162 170
15. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis: 2005; 40 5 704 708
16. Palmer S. M., Limaye A. P., Banks M., et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med: 2010; 152 12 761 769
17. Arthurs S. K., Eid A. J., Pedersen R. A., et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis: 2008; 46 6 840 846
18. Blyth D., Lee I., Sims K. D., et al. Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation. Transpl Infect Dis: 2012; 14 2 149 155
19. Limaye A. P., Bakthavatsalam R., Kim H. W., et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation: 2006; 81 12 1645 1652
20. Fishman J. A. Infection in solid-organ transplant recipients. N Engl J Med: 2007; 357 25 2601 2614
21. Lautenschlager I., Halme L., Höckerstedt K., Krogerus L., Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis: 2006; 8 1 21 30
22. Snydman D. R., Limaye A. P., Potena L., Zamora M. R. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc: 2011; 43 (3, Suppl): S1 S17
23. Peleg A. Y., Husain S., Kwak E. J., et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis: 2007; 44 2 204 212
24. Sagedal S., Rollag H., Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant: 2007; 21 3 309 313
25. Hodson E. M., Craig J. C., Strippoli G. F., Webster A. C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev: 2008; 2 CD003774
26. Hodson E. M., Jones C. A., Webster A. C., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet: 2005; 365 9477 2105 2115
27. George M. J., Snydman D. R., Werner B. G., et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med: 1997; 103 2 106 113
28. Walker R. C., Marshall W. F., Strickler J. G., et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis: 1995; 20 5 1346 1353
29. Nichols W. G., Corey L., Gooley T., Davis C., Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis: 2002; 185 3 273 282
30. Estenne M., Maurer J. R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant: 2002; 21 3 297 310
31. Evans P. C., Soin A., Wreghitt T. G., Taylor C. J., Wight D. G., Alexander G. J. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation: 2000; 69 1 30 35
32. Koskinen P. K., Kallio E. A., Tikkanen J. M., Sihvola R. K., Häyry P. J., Lemström K. B. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis: 1999; 1 2 115 126
33. Nett P. C., Heisey D. M., Fernandez L. A., Sollinger H. W., Pirsch J. D. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation: 2004; 78 7 1036 1041
34. Erdbruegger U., Scheffner I., Mengel M., et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant: 2012; 27 1 435 443
35. Kranz B., Vester U., Wingen A. M., et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant: 2008; 12 4 474 478
36. Sagedal S., Nordal K. P., Hartmann A., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant: 2002; 2 9 850 856
37. Reischig T., Jindra P., Svecová M., Kormunda S., Opatrný K. Jr, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol: 2006; 36 2 146 151
38. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant: 2008; 8 5 975 983
39. Humar A., Gillingham K. J., Payne W. D., Dunn D. L., Sutherland D. E., Matas A. J. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation: 1999; 68 12 1879 1883
40. Razonable R. R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis: 2001; 184 11 1461 1464
41. Kruger R. M., Shannon W. D., Arens M. Q., Lynch J. P., Storch G. A., Trulock E. P. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation: 1999; 68 9 1272 1279
42. Paraskeva M., Bailey M., Levvey B. J., et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant: 2011; 11 10 2190 2196
43. Westall G. P., Michaelides A., Williams T. J., Snell G. I., Kotsimbos T. C. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation: 2003; 75 12 2064 2068
44. Valantine H. A., Gao S. Z., Menon S. G., et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation: 1999; 100 1 61 66
45. Lemström K., Koskinen P., Krogerus L., Daemen M., Bruggeman C., Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation: 1995; 92 9 2594 2604
46. Dickenmann M. J., Cathomas G., Steiger J., Mihatsch M. J., Thiel G., Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation: 2001; 71 6 764 767
47. Chemaly R. F., Yen-Lieberman B., Chapman J., et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant: 2005; 5 3 544 548
48. Schlischewsky E., Fuehner T., Warnecke G., et al. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis: 2013; 15 1 60 69
49. Bosch W., Heckman M. G., Pungpapong S., Diehl N. N., Shalev J. A., Hellinger W. C. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation: 2012; 93 7 723 728
50. Rayes N., Seehofer D., Lullius S. G., et al. Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study. Ann Transplant: 2005; 10 2 23 28
51. Emery V. C., Sabin C. A., Cope A. V., Gor D., Hassan-Walker A. F., Griffiths P. D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet: 2000; 355 9220 2032 2036
52. Cope A. V., Sabin C., Burroughs A., Rolles K., Griffiths P. D., Emery V. C. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis: 1997; 176 6 1484 1490
53. Kotton C. N., Kumar D., Caliendo A. M., et al. Transplantation Society International CMV Consensus Group International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation: 2010; 89 7 779 795
54. Pang X. L., Fox J. D., Fenton J. M., Miller G. G., Caliendo A. M., Preiksaitis J. K. American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant: 2009; 9 2 258 268
55. Caliendo A. M., Schuurman R., Yen-Lieberman B., et al. CMV Working Group of the Complications of HIV Disease RAC, AIDS Clinical Trials Group Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol: 2001; 39 4 1334 1338
56. Grim S. A., Pereira E., Guzman G., Clark N. M. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation: 2010; 90 7 799 801
57. Mazzulli T., Drew L. W., Yen-Lieberman B., et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol: 1999; 37 4 958 963
58. Humar A., Mazzulli T., Moussa G., et al. Valganciclovir Solid Organ Transplant Study Group Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant: 2005; 5 5 1065 1070
59. Weber B., Fall E. M., Berger A., Doerr H. W. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol: 1999; 14 3 173 181
60. Pillay D., Ali A. A., Liu S. F., Kops E., Sweny P., Griffiths P. D. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation: 1993; 56 1 103 108
61. Buffone G. J., Frost A., Samo T., Demmler G. J., Cagle P. T., Lawrence E. C. The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. Transplantation: 1993; 56 2 342 347
62. Storch G. A., Ettinger N. A., Ockner D., et al. Quantitative cultures of the cell fraction and supernatant of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis in lung transplant recipients. J Infect Dis: 1993; 168 6 1502 1506
63. Westall G. P., Michaelides A., Williams T. J., Snell G. I., Kotsimbos T. C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis: 2004; 190 6 1076 1083
64. Cervera C., Lozano F., Linares L., et al. Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation. Transplant Proc: 2009; 41 6 2259 2261
65. Cervera C., Lozano F., Saval N., et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation: 2007; 83 11 1493 1500
66. Kwakkel-van Erp J. M., Paantjens A. W., van Kessel D. A., et al. Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol: 2011; 165 3 410 416
67. Doron S., Ruthazer R., Werner B. G., Rabson A., Snydman D. R. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation: 2006; 81 5 697 703
68. Goldfarb N. S., Avery R. K., Goormastic M., et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation: 2001; 71 2 242 246
69. Beam E., Razonable R. R. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep: 2012; 14 6 633 641
70. Asberg A., Humar A., Rollag H., et al. VICTOR Study Group Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: 2007; 7 9 2106 2113
71. Asberg A., Humar A., Jardine A. G., et al. VICTOR Study Group Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant: 2009; 9 5 1205 1213
72. Humar A., Kumar D., Boivin G., Caliendo A. M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis: 2002; 186 6 829 833
73. Boivin G., Goyette N., Gilbert C., Humar A., Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis: 2005; 7 3-4 166 170
74. Limaye A. P., Corey L., Koelle D. M., Davis C. L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet: 2000; 356 9230 645 649
75. Limaye A. P., Raghu G., Koelle D. M., Ferrenberg J., Huang M. L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis: 2002; 185 1 20 27
76. Mylonakis E., Kallas W. M., Fishman J. A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis: 2002; 34 10 1337 1341
77. Zuk D. M., Humar A., Weinkauf J. G., Lien D. C., Nador R. G., Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation: 2010; 90 6 672 676
78. Avery R. K., Marty F. M., Strasfeld L., et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis: 2010; 12 6 489 496
79. Marschall M., Stamminger T., Urban A., et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother: 2012; 56 2 1135 1137
80. Härter G., Michel D. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother: 2012; 13 5 623 627
81. Kaul D. R., Stoelben S., Cober E., et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant: 2011; 11 5 1079 1084
82. Levi M. E., Mandava N., Chan L. K., Weinberg A., Olson J. L. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis: 2006; 8 1 38 43
83. Aspord C., Laurin D., Richard M. J., Vie H., Chaperot L., Plumas J. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases. Am J Transplant: 2011; 11 12 2613 2626
84. Small L. N., Lau J., Snydman D. R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis: 2006; 43 7 869 880
85. Opelz G., Döhler B., Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant: 2004; 4 6 928 936
86. Malouf M. A., Chhajed P. N., Hopkins P., Plit M., Turner J., Glanville A. R. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant: 2002; 21 5 547 554
87. Munoz-Price L. S., Slifkin M., Ruthazer R., et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis: 2004; 39 9 1293 1299
88. Levitsky J., Singh N., Wagener M. M., Stosor V., Abecassis M., Ison M. G. A survey of CMV prevention strategies after liver transplantation. Am J Transplant: 2008; 8 1 158 161
89. Snydman D. R., Falagas M. E., Avery R., et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc: 2001; 33 4 2571 2575
90. Snydman D. R., Werner B. G., Dougherty N. N., et al. Boston Center for Liver Transplantation CMVIG Study Group Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med: 1993; 119 10 984 991
91. Zamora M. R., Nicolls M. R., Hodges T. N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant: 2004; 4 10 1635 1642
92. Humar A., Paya C., Pescovitz M. D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant: 2004; 4 4 644 649
93. Westall G. P., Mifsud N. A., Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant: 2008; 8 8 1749 1754
94. Griffiths P. D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet: 2011; 377 9773 1256 1263
95. Kharfan-Dabaja M. A., Boeckh M., Wilck M. B., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis: 2012; 12 4 290 299
96. Xu F., Sternberg M. R., Kottiri B. J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA: 2006; 296 8 964 973
97. Nahmias A. J., Roizman B. Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med: 1973; 289 15 781 789
98. Corey L., Spear P. G. Infections with herpes simplex viruses (1). N Engl J Med: 1986; 314 11 686 691
99. Kimberlin D. W., Rouse D. J. Clinical practice: genital herpes. N Engl J Med: 2004; 350 19 1970 1977
100. Engelberg R., Carrell D., Krantz E., Corey L., Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis: 2003; 30 2 174 177
101. Lafferty W. E., Coombs R. W., Benedetti J., Critchlow C., Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med: 1987; 316 23 1444 1449
102. Whitley R. J. Viral encephalitis. N Engl J Med: 1990; 323 4 242 250
103. Kusne S., Schwartz M., Breinig M. K., et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis: 1991; 163 5 1001 1007
104. Holland H. K., Wingard J. R., Saral R. Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies. Cancer Invest: 1990; 8 5 509 521
105. Smyth R. L., Higenbottam T. W., Scott J. P., et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation: 1990; 49 4 735 739
106. Dummer J. S., Armstrong J., Somers J., et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis: 1987; 155 2 202 206
107. Engelmann I., Hesse N., Fegbeutel C., et al. Incidence and impact of herpes simplex and cytomegalovirus detection in the respiratory tract after lung transplantation. Transpl Infect Dis: 2011; 13 3 259 265
108. Singh N., Dummer J. S., Kusne S., et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis: 1988; 158 1 124 131
109. Engelmann I., Gottlieb J., Meier A., et al. Clinical relevance of and risk factors for HSV-related tracheobronchitis or pneumonia: results of an outbreak investigation. Crit Care: 2007; 11 6 R119
110. Lavery E. A., Coyle W. J. Herpes simplex virus and the alimentary tract. Curr Gastroenterol Rep: 2008; 10 4 417 423
111. Lafferty W. E., Krofft S., Remington M., et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol: 1987; 25 2 323 326
112. Ramaswamy M., McDonald C., Smith M., et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect: 2004; 80 5 406 410
113. Boivin G. Diagnosis of herpesvirus infections of the central nervous system. Herpes: 2004; 11 02 48A 56A
114. Management of herpes virus infections following transplantation. J Antimicrob Chemother: 2000; 45 6 729 748
115. Chou S., Gallagher J. G., Merigan T. C. Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet: 1981; 1 8235 1392 1394
116. Tan H. H., Goh C. L. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol: 2006; 7 1 13 29
117. Danve-Szatanek C., Aymard M., Thouvenot D., et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol: 2004; 42 1 242 249
118. Sauerbrei A., Taut J., Zell R., Wutzler P. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res: 2011; 90 3 242 247
119. Sorensen G. V., Rosthoj S., Würtz M., Danielsen T. K., Schroder H. The epidemiology of herpes zoster in 226 children with acute lymphoblastic leukemia. Pediatr Blood Cancer: 2011; 57 6 993 997
120. Su S. H., Martel-Laferrière V., Labbé A. C., et al. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: 2011; 17 7 1012 1017
121. Pergam S. A., Forsberg C. W., Boeckh M. J., et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis: 2011; 13 1 15 23
122. Razonable R. R., Brown R. A., Humar A., Covington E., Alecock E., Paya C. V. PV16000 Study Group Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis: 2005; 192 8 1331 1339
123. Mustapic Z., Basic-Jukic N., Kes P., et al. Varicella zoster infection in renal transplant recipients: prevalence, complications and outcome. Kidney Blood Press Res: 2011; 34 6 382 386
124. Manuel O., Kumar D., Singer L. G., Cobos I., Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant: 2008; 27 1 11 16
125. Gnann J. W. Jr, Whitley R. J. Clinical practice: herpes zoster. N Engl J Med: 2002; 347 5 340 346
126. Chow J., Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis: 2009; 49 10 1550 1556
127. Gershon A. A., Gershon M. D., Breuer J., Levin M. J., Oaklander A. L., Griffiths P. D. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol: 2010; 48 01 S2 S7
128. Wiegering V., Schick J., Beer M., et al. Varicella-zoster virus infections in immunocompromised patients-a single centre 6-years analysis. BMC Pediatr: 2011; 11 31
129. Matsuzaki A., Suminoe A., Koga Y., et al. Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol: 2008; 25 3 237 242
130. Buchbinder S. P., Katz M. H., Hessol N. A., et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis: 1992; 166 5 1153 1156
131. Leung T. F., Chik K. W., Li C. K., et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant: 2000; 25 2 167 172
132. Levitsky J., Kalil A., Meza J. L., Hurst G. E., Freifeld A. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl: 2005; 11 3 320 325
133. Lévêque N., Galambrun C., Najioullah F., Bleyzac N., Pages M. P., Bertrand Y. Two cases of varicella zoster virus meningitis found in pediatric patients after bone marrow transplantation despite valaciclovir prophylaxis and without skin lesions. J Med Virol: 2006; 78 4 514 516
134. Brink A. A., van Gelder M., Wolffs P. F., Bruggeman C. A., van Loo I. H. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis: 2011; 52 8 982 987
135. Tarabishy A. B., Khatib O. F., Nocero J. R., Budev M., Kaiser P. K. Ocular complications in patients with lung transplants. Br J Ophthalmol: 2011; 95 9 1295 1298
136. Lee M. Y., Kim K. S., Lee W. K. Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. Ocul Immunol Inflamm: 2011; 19 3 212 213
137. Rogers J. E., Cumpston A., Newton M., Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis: 2011; 13 5 480 484
138. Han C. S., Miller W., Haake R., Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant: 1994; 13 3 277 283
139. Kalpoe J. S., Kroes A. C., Verkerk S., Claas E. C., Barge R. M., Beersma M. F. Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation. Bone Marrow Transplant: 2006; 38 1 41 46
140. Kim S. J., Kim K., Do Y. R., Bae S. H., Yang D. H., Lee J. J. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol: 2011; 41 3 353 357
141. Fuks L., Shitrit D., Fox B. D., et al. Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann Thorac Surg: 2009; 87 2 423 426
142. Gourishankar S., McDermid J. C., Jhangri G. S., Preiksaitis J. K. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant: 2004; 4 1 108 115
143. Arness T., Pedersen R., Dierkhising R., Kremers W., Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis: 2008; 10 4 260 268
144. Herrero J. I., Quiroga J., Sangro B., et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl: 2004; 10 9 1140 1143
145. Hsu R. B., Fang C. T., Chang S. C., et al. Infectious complications after heart transplantation in Chinese recipients. Am J Transplant: 2005; 5 8 2011 2016
146. Dworkin R. H., Johnson R. W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis: 2007; 44 01 S1 S26
147. Hatchette T., Tipples G. A., Peters G., Alsuwaidi A., Zhou J., Mailman T. L. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J: 2008; 27 1 75 77
148. Visse B., Dumont B., Huraux J. M., Fillet A. M. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis: 1998; 178 01 S55 S57
149. Boeckh M., Kim H. W., Flowers M. E., Meyers J. D., Bowden R. A. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood: 2006; 107 5 1800 1805
150. Erard V., Guthrie K. A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood: 2007; 110 8 3071 3077
151. Oxman M. N., Levin M. J., Johnson G. R., et al. Shingles Prevention Study Group A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med: 2005; 352 22 2271 2284
152. Sanford M., Keating G. M. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging: 2010; 27 2 159 176
153. Löbermann M., Boršo D., Hilgendorf I., Fritzsche C., Zettl U. K., Reisinger E. C. Immunization in the adult immunocompromised host. Autoimmun Rev: 2012; 11 3 212 218
154. Avery R. K., Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant: 2008; 8 1 9 14
155. Cohen J. I. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis: 2008; 197 02 S237 S241
156. Danzinger-Isakov L., Kumar D. AST Infectious Diseases Community of Practice Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant: 2009; 9 04 S258 S262
157. Centers for Disease Control and Prevention, Infectious Disease Society of America America Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep: 2000; 49 RR-10 1 125
158. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant: 2004; 4 10 160 163
159. Lennette E. T., Blackbourn D. J., Levy J. A. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet: 1996; 348 9031 858 861
160. Cesarman E., Chang Y., Moore P. S., Said J. W., Knowles D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med: 1995; 332 18 1186 1191
161. De Bolle L., Naesens L., De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev: 2005; 18 1 217 245
162. Dockrell D. H. Human herpesvirus 6: molecular biology and clinical features. J Med Microbiol: 2003; 52 Pt 1 5 18
163. Black J. B., Pellett P. E. Human herpesvirus 7. Rev Med Virol: 1999; 9 4 245 262
164. Okuno T., Takahashi K., Balachandra K., et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol: 1989; 27 4 651 653
165. Emery V. C. Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis: 2001; 32 9 1357 1360
166. Michaelides A., Glare E. M., Spelman D. W., et al. beta-Herpesvirus (human cytomegalovirus and human herpesvirus 6) reactivation in at-risk lung transplant recipients and in human immunodeficiency virus-infected patients. J Infect Dis: 2002; 186 2 173 180
167. Manuel O., Kumar D., Moussa G., et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation: 2009; 87 5 719 725
168. Lautenschlager I., Razonable R. R. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int: 2012; 25 5 493 502
169. Ariza-Heredia E. J., Razonable R. R. Human herpes virus 8 in solid organ transplantation. Transplantation: 2011; 92 8 837 844
170. Butler L. M., Were W. A., Balinandi S., et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. J Infect Dis: 2011; 203 5 625 634
171. Bergallo M., Costa C., Margio S., et al. Human herpes virus 8 infection in kidney transplant patients from an area of northwestern Italy (Piemonte region). Nephrol Dial Transplant: 2007; 22 6 1757 1761
172. Einollahi B., Lessan-Pezeshki M., Nourbala M. H., et al. Kaposi's sarcoma following living donor kidney transplantation: review of 7,939 recipients. Int Urol Nephrol: 2009; 41 3 679 685
173. Gao S. J., Kingsley L., Li M., et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med: 1996; 2 8 925 928
174. Engels E. A., Atkinson J. O., Graubard B. I., et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis: 2007; 196 2 199 207
175. Martin J. N., Ganem D. E., Osmond D. H., Page-Shafer K. A., Macrae D., Kedes D. H. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med: 1998; 338 14 948 954
176. Regamey N., Cathomas G., Schwager M., Wernli M., Harr T., Erb P. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol: 1998; 36 6 1784 1786
177. Verbeek W., Frankel M., Miles S., Said J., Koeffler H. P. Seroprevalence of HHV-8 antibodies in HIV-positive homosexual men without Kaposi's sarcoma and their clinical follow-up. Am J Clin Pathol: 1998; 109 6 778 783
178. Cannon M. J., Dollard S. C., Smith D. K., et al. HIV Epidemiology Research Study Group Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med: 2001; 344 9 637 643
179. Luppi M., Barozzi P., Santagostino G., et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood: 2000; 96 9 3279 3281
180. Humar A., Asberg A., Kumar D., et al. VICTOR study group An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant: 2009; 9 2 374 381
181. Herbein G., Strasswimmer J., Altieri M., Woehl-Jaegle M. L., Wolf P., Obert G. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin Infect Dis: 1996; 22 1 171 173
182. Humar A., Kumar D., Caliendo A. M., et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation: 2002; 73 4 599 604
183. Ljungman P., Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol: 2006; 37 01 S87 S91
184. Nash P. J., Avery R. K., Tang W. H., Starling R. C., Taege A. J., Yamani M. H. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant: 2004; 4 7 1200 1203
185. Singh N., Carrigan D. R., Gayowski T., Singh J., Marino I. R. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation: 1995; 60 11 1355 1357
186. Vu T., Carrum G., Hutton G., Heslop H. E., Brenner M. K., Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant: 2007; 39 11 705 709
187. Noguchi T., Yoshiura T., Hiwatashi A., et al. CT and MRI findings of human herpesvirus 6-associated encephalopathy: comparison with findings of herpes simplex virus encephalitis. AJR Am J Roentgenol: 2010; 194 3 754 760
188. Seeley W. W., Marty F. M., Holmes T. M., et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology: 2007; 69 2 156 165
189. Other herpesviruses: HHV-6, HHV-7, HHV-8, HSV-1 and -2, VZV. Am J Transplant: 2004; 4 10 66 71
190. Lautenschlager I., Linnavuori K., Höckerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation: 2000; 69 12 2561 2566
191. Griffiths P. D., Ait-Khaled M., Bearcroft C. P., et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol: 1999; 59 4 496 501
192. Costa C., Curtoni A., Bergallo M., et al. Quantitative detection of HHV-6 and HHV-7 in transbronchial biopsies from lung transplant recipients. New Microbiol: 2011; 34 3 275 280
193. Luppi M., Barozzi P., Schulz T. F., et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med: 2000; 343 19 1378 1385
194. Moosa M. R. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM: 2005; 98 3 205 214
195. Al-Khader A. A., Suleiman M., Al-Hasani M., Haleem A. Posttransplant Kaposi sarcoma: staging as a guide to therapy and prognosis. Nephron: 1988; 48 2 165
196. Al Otaibi T., Al Sagheir A., Ludwin D., Meyer R. Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report. Transplant Proc: 2007; 39 4 1276 1277
197. Gaitonde S., Vidanovic V., Ni H. Concomitant and fatal HHV-8+ multicentric Castleman's disease and Kaposi's sarcoma in the same lymph node of an HIV- liver transplant patient. Histopathology: 2007; 50 7 954 958
198. Lim E. J., Crowley P., Mitchell C. A., Angus P. W. Post-liver transplantation multicentric Castleman disease treated with valganciclovir and weaning of immunosuppression. Am J Transplant: 2011; 11 1 169 172
199. Boulanger E., Afonso P. V., Yahiaoui Y., Adle-Biassette H., Gabarre J., Agbalika F. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant: 2008; 8 3 707 710
200. Dotti G., Fiocchi R., Motta T., et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia: 1999; 13 5 664 670
201. Jones D., Ballestas M. E., Kaye K. M., et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med: 1998; 339 7 444 449
202. Lautenschlager I., Razonable R. R. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int: 2012; 25 5 493 502
203. Boutolleau D., Duros C., Bonnafous P., et al. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol: 2006; 35 3 257 263
204. Safronetz D., Humar A., Tipples G. A. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J Virol Methods: 2003; 112 1-2 99 105
205. Tedeschi R., Marus A., Bidoli E., Simonelli C., De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol: 2008; 43 3 255 259
206. Tedeschi R., Enbom M., Bidoli E., Linde A., De Paoli P., Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol: 2001; 39 12 4269 4273
207. De Clercq E., Naesens L., De Bolle L., Schols D., Zhang Y., Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol: 2001; 11 6 381 395
208. Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis: 2002; 186 01 S99 S109
209. Brennan D. C., Storch G. A., Singer G. G., Lee L., Rueda J., Schnitzler M. A. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis: 2000; 181 5 1557 1561
210. Wang F. Z., Dahl H., Linde A., Brytting M., Ehrnst A., Ljungman P. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood: 1996; 88 9 3615 3620
211. Monaco A. P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation: 2009; 87 2 157 163
212. Régnier-Rosencher E., Barrou B., Marcelin A. G., et al. Primary effusion lymphoma in two kidney transplant recipients [in French]. Ann Dermatol Venereol: 2010; 137 4 285 289
213. Nourse J. P., Jones K., Gandhi M. K. Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant: 2011; 11 5 888 895
214. Gottschalk S., Rooney C. M., Heslop H. E. Post-transplant lymphoproliferative disorders. Annu Rev Med: 2005; 56 29 44
215. Preiksaitis J. K. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis: 2004; 39 7 1016 1023
216. Weigt S. SLL, Fishbein M. C., Lynch J. P. III. Lymphoproliferative disorders complicating solid organ transplantation. In: Lynch J. P. III, Ross D. J., eds. Lung and Heart-Lung Transplantation. New York, NY Taylor & Francis: 2006; 217 901 934
217. Ramalingam P., Rybicki L., Smith M. D., et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol: 2002; 15 6 647 656
218. Ziarkiewicz-Wróblewska B., Górnicka B., Ołdakowska U., et al. Plasmacytic hyperplasia-the early form of posttransplant lymphoproliferative disorder-with atypical morphology and clinical course in patient after liver transplantation: a case report. Transplant Proc: 2003; 35 6 2320 2322
219. Zamora M. R. DNA viruses (CMV, EBV, and the herpesviruses). Semin Respir Crit Care Med: 2011; 32 4 454 470
220. Lundell R., Elenitoba-Johnson K. S., Lim M. S. T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol: 2004; 28 7 967 973
221. Sebire N. J., Malone M., Ramsay A. D. Posttransplant lymphoproliferative disorder presenting as CD30+, ALK+, anaplastic large cell lymphoma in a child. Pediatr Dev Pathol: 2004; 7 3 290 293
222. Bustillo M., Perez Melon C., Otero Glz A., et al. High grade lymphoma in a post-renal transplant patient. Description of a case and literature review. Nephron: 2000; 84 2 189 191
223. Orjuela M. A., Alobeid B., Liu X., et al. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. Br J Haematol: 2011; 152 6 733 742
224. Maecker B., Jack T., Zimmermann M., et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol: 2007; 25 31 4902 4908
225. Opelz G., Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant: 2004; 4 2 222 230
226. Cohen J. I. Epstein-Barr virus infection. N Engl J Med: 2000; 343 7 481 492
227. Crawford D. H., Macsween K. F., Higgins C. D., et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis: 2006; 43 3 276 282
228. Gulley M. L., Swinnen L. J., Plaisance K. T. Jr, Schnell C., Grogan T. M., Schneider B. G. Southwest Oncology Group Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation: 2003; 76 6 959 964
229. Verschuuren E., van der Bij W., de Boer W., Timens W., Middeldorp J., The T. H. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol: 2003; 69 2 258 266
230. Holman C. J., Karger A. B., Mullan B. D., Brundage R. C., Balfour H. H. Jr. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant: 2012; 26 5 741 747
231. Birkeland S. A., Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation: 2003; 76 6 984 988
232. Wigle D. A., Chaparro C., Humar A., Hutcheon M. A., Chan C. K., Keshavjee S. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation: 2001; 72 11 1783 1786
233. Hachem R. R., Chakinala M. M., Yusen R. D., et al. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation: 2004; 77 3 431 437
234. Paranjothi S., Yusen R. D., Kraus M. D., Lynch J. P., Patterson G. A., Trulock E. P. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant: 2001; 20 10 1054 1063
235. Siegel M. J., Lee E. Y., Sweet S. C., Hildebolt C. CT of posttransplantation lymphoproliferative disorder in pediatric recipients of lung allograft. AJR Am J Roentgenol: 2003; 181 4 1125 1131
236. Angel L. F., Cai T. H., Sako E. Y., Levine S. M. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant: 2000; 5 3 26 30
237. Lim G. Y., Newman B., Kurland G., Webber S. A. Posttransplantation lymphoproliferative disorder: manifestations in pediatric thoracic organ recipients. Radiology: 2002; 222 3 699 708
238. Pickhardt P. J., Siegel M. J. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology: 1999; 213 1 73 78
239. Armitage J. M., Kormos R. L., Stuart R. S., et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant: 1991; 10 6 877 886, discussion 886-887
240. Reams B. D., McAdams H. P., Howell D. N., Steele M. P., Davis R. D., Palmer S. M. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest: 2003; 124 4 1242 1249
241. Gong J. Z., Stenzel T. T., Bennett E. R., et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol: 2003; 27 6 818 827
242. Swerdlow S. HWS, Chadburn A., Ferry J. A. Post-transplant lymphopliferative disorders. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon International Agency for Research on Cancer: 2008; 343 349
243. Tsai D. E., Douglas L., Andreadis C., et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant: 2008; 8 5 1016 1024
244. Bordon V., Padalko E., Benoit Y., Dhooge C., Laureys G. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. Pediatr Transplant: 2012; 16 2 144 150
245. Rappaport D. C., Chamberlain D. W., Shepherd F. A., Hutcheon M. A. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology: 1998; 206 2 519 524
246. Scarsbrook A. F., Warakaulle D. R., Dattani M., Traill Z. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol: 2005; 60 1 47 55
247. Marom E. M., McAdams H. P., Butnor K. J., Coleman R. E. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging: 2004; 19 2 74 78
248. Wong J. Y., Tait B., Levvey B., et al. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation: 2004; 78 2 205 210
249. Aris R. M., Maia D. M., Neuringer I. P., et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med: 1996; 154 6 Pt 1 1712 1717
250. Sampaio M. S., Cho Y. W., Shah T., Bunnapradist S., Hutchinson I. V. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant: 2012; 27 7 2971 2979
251. Gao S. Z., Chaparro S. V., Perlroth M., et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant: 2003; 22 5 505 514
252. Hurwitz M., Desai D. M., Cox K. L., Berquist W. E., Esquivel C. O., Millan M. T. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant: 2004; 8 3 267 272
253. Cherikh W. S., Kauffman H. M., McBride M. A., Maghirang J., Swinnen L. J., Hanto D. W. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation: 2003; 76 9 1289 1293
254. Manlhiot C., Pollock-Barziv S. M., Holmes C., et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant: 2010; 29 6 648 657
255. Duvoux C., Pageaux G. P., Vanlemmens C., et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation: 2002; 74 8 1103 1109
256. Swinnen L. J., Costanzo-Nordin M. R., Fisher S. G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med: 1990; 323 25 1723 1728
257. Worth A., Conyers R., Cohen J., et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol: 2011; 155 3 377 385
258. Saueressig M. G., Boussaud V., Amrein C., Guillemain R., Souilamas J., Souilamas R. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant: 2011; 25 4 E430 E436
259. Soler M. J., Puig J. M., Mir M., et al. Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients. Transplant Proc: 2003; 35 5 1709 1713
260. Leblond V., Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol: 2004; 40 5 728 735
261. Fernández M. C., Bes D., De Dávila M., et al. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. Pediatr Transplant: 2009; 13 3 307 310
262. Draoua H. Y., Tsao L., Mancini D. M., Addonizio L. J., Bhagat G., Alobeid B. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol: 2004; 127 4 429 432
263. Aull M. J., Buell J. F., Trofe J., et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation: 2004; 78 11 1676 1682
264. Krumbholz A., Sandhaus T., Göhlert A., et al. Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol (Berl): 2010; 199 4 317 322
265. Engelmann I., Welte T., Fühner T., et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol: 2009; 45 1 47 53
266. Neurohr C., Huppmann P., Leuchte H., et al. Munich Lung Transplant Group Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant: 2005; 5 12 2982 2991
267. Caillard S., Lamy F. X., Quelen C., et al. French Transplant Centers Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant: 2012; 12 3 682 693
268. Swinnen L. J., Mullen G. M., Carr T. J., Costanzo M. R., Fisher R. I. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood: 1995; 86 9 3333 3340
269. Verschuuren E. A., Stevens S. J., van Imhoff G. W., et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation: 2002; 73 1 100 104
270. Evens A. M., David K. A., Helenowski I., et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol: 2010; 28 6 1038 1046
271. Oton A. B., Wang H., Leleu X., et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma: 2008; 49 9 1738 1744
272. Chan T. S., Hwang Y. Y., Gill H., et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant: 2012; 26 5 679 683
273. Sherritt M. A., Bharadwaj M., Burrows J. M., et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation: 2003; 75 9 1556 1560
274. Styczynski J., Einsele H., Gil L., Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis: 2009; 11 5 383 392
275. Doubrovina E., Oflaz-Sozmen B., Prockop S. E., et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood: 2012; 119 11 2644 2656
276. Funch D. P., Walker A. M., Schneider G., Ziyadeh N. J., Pescovitz M. D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant: 2005; 5 12 2894 2900
277. Hirsch H. H., Steiger J. Polyomavirus BK. Lancet Infect Dis: 2003; 3 10 611 623
278. Kazory A., Ducloux D. Renal transplantation and polyomavirus infection: recent clinical facts and controversies. Transpl Infect Dis: 2003; 5 2 65 71
279. Johnston O., Jaswal D., Gill J. S., Doucette S., Fergusson D. A., Knoll G. A. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation: 2010; 89 9 1057 1070
280. Renoult E., Coutlée F., Pâquet M., et al. Evaluation of a preemptive strategy for BK polyomavirus-associated nephropathy based on prospective monitoring of BK viremia: a kidney transplantation center experience. Transplant Proc: 2010; 42 10 4083 4087
281. Dropulic L. K., Jones R. J. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant: 2008; 41 1 11 18
282. Cesaro S., Hirsch H. H., Faraci M., et al. European Group for Blood and Marrow Transplantation Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis: 2009; 49 2 233 240
283. Khan H., Oberoi S., Mahvash A., et al. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant: 2011; 17 10 1551 1555
284. Brennan D. C., Agha I., Bohl D. L., et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant: 2005; 5 3 582 594
285. Bressollette-Bodin C., Coste-Burel M., Hourmant M., Sebille V., Andre-Garnier E., Imbert-Marcille B. M. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant: 2005; 5 8 1926 1933
286. Cesaro S., Facchin C., Tridello G., et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant: 2008; 41 4 363 370
287. Doucette K. E., Pang X. L., Jackson K., et al. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation: 2008; 85 12 1733 1736
288. Muñoz P., Fogeda M., Bouza E., Verde E., Palomo J., Bañares R. BKV Study Group Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis: 2005; 41 12 1720 1725
289. Razonable R. R., Brown R. A., Humar A., Covington E., Alecock E., Paya C. V. PV16000 Study Group A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis: 2005; 192 8 1349 1354
290. Amir A., Shapiro R., Shulman L. M., et al. BK virus infection and its effect on renal function in pediatric liver-transplant recipients: a cross-sectional, longitudinal, prospective study. Transplantation: 2011; 92 8 943 946
291. Thomas L. D., Milstone A. P., Vilchez R. A., Zanwar P., Butel J. S., Dummer J. S. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation: 2009; 88 3 360 366
292. Thomas L. D., Vilchez R. A., White Z. S., et al. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis: 2007; 195 3 442 449
293. Purighalla R., Shapiro R., McCauley J., Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis: 1995; 26 4 671 673
294. Hirsch H. H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med: 2002; 347 7 488 496
295. Hirsch H. H., Brennan D. C., Drachenberg C. B., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation: 2005; 79 10 1277 1286
296. Randhawa P. S., Demetris A. J. Nephropathy due to polyomavirus type BK. N Engl J Med: 2000; 342 18 1361 1363
297. Egli A., Helmersen D. S., Taub K., Hirsch H. H., Johnson A. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant: 2010; 10 10 2324 2330
298. Gorczynska E., Turkiewicz D., Rybka K., et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant: 2005; 11 10 797 804
299. Drachenberg C. B., Papadimitriou J. C., Ramos E. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: a shifting paradigm? Clin J Am Soc Nephrol: 2006; 1 3 374 379
300. Limaye A. P., Smith K. D., Cook L., et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant: 2005; 5 3 614 620
301. Schmid H., Burg M., Kretzler M., Banas B., Gröne H. J., Kliem V. BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant: 2005; 5 6 1562 1568
302. Barber C. E., Hewlett T. J., Geldenhuys L., Kiberd B. A., Acott P. D., Hatchette T. F. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis: 2006; 8 2 113 121
303. Haririan A., Ramos E. R., Drachenberg C. B., Weir M. R., Klassen D. K. Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. Transplantation: 2002; 73 8 1350 1353
304. Schwarz A., Mengel M., Haller H., Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant: 2005; 5 10 2582 2585
305. Elidemir O., Chang I. F., Schecter M. G., Mallory G. B. BK virus-associated hemorrhagic cystitis in a pediatric lung transplant recipient. Pediatr Transplant: 2007; 11 7 807 810
306. Schaub S., Hirsch H. H., Dickenmann M., et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus- associated nephropathy. Am J Transplant: 2010; 10 12 2615 2623
307. Hilton R., Tong C. Y. Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J Antimicrob Chemother: 2008; 62 5 855 859
308. Saad E. R., Bresnahan B. A., Cohen E. P., et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation: 2008; 85 6 850 854
309. Williams J. W., Javaid B., Kadambi P. V., et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med: 2005; 352 11 1157 1158
310. Liacini A., Seamone M. E., Muruve D. A., Tibbles L. A. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation: 2010; 90 12 1450 1457
311. Faraci M., Cuzzubbo D., Lanino E., et al. Low dosage cidofovir without probenecid as treatment for BK virus hamorrhagic cystitis after hemopoietic stem cell transplant. Pediatr Infect Dis J: 2009; 28 1 55 57
312. Sener A., House A. A., Jevnikar A. M., et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation: 2006; 81 1 117 120
313. Chang C. Y., Gangji A., Chorneyko K., Kapoor A. Urological manifestations of BK polyomavirus in renal transplant recipients. Can J Urol: 2005; 12 5 2829 2836
314. Mateen F. J., Muralidharan R., Carone M., et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol: 2011; 70 2 305 322
315. Bellizzi A., Nardis C., Anzivino E., et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol: 2012; 18 1 1 11
316. Ouwens J. P., Haaxma-Reiche H., Verschuuren E. A., et al. Groningen Lung Transplant Group Visual symptoms after lung transplantation: a case of progressive multifocal leukoencephalopathy. Transpl Infect Dis: 2000; 2 1 29 32
317. Aksamit A. J. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist: 2006; 12 6 293 298
318. Tavazzi E., Ferrante P., Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect: 2011; 17 12 1776 1780
319. Egli A., Infanti L., Dumoulin A., et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis: 2009; 199 6 837 846
320. Sabath B. F., Major E. O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis: 2002; 186 02 S180 S186
321. Tan C. S., Koralnik I. J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol: 2010; 9 4 425 437
322. Cinque P., Koralnik I. J., Gerevini S., Miro J. M., Price R. W. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis: 2009; 9 10 625 636
323. Delbue S., Branchetti E., Boldorini R., et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J Med Virol: 2008; 80 12 2147 2152
324. Tan C. S., Dezube B. J., Bhargava P., et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis: 2009; 199 6 881 888
325. Chapagain M. L., Nerurkar V. R. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis: 2010; 202 2 184 191
326. Maginnis M. S., Atwood W. J. JC virus: an oncogenic virus in animals and humans? Semin Cancer Biol: 2009; 19 4 261 269
327. Wenning W., Haghikia A., Laubenberger J., et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med: 2009; 361 11 1075 1080
328. Del Valle L., White M. K., Khalili K. Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol: 2008; 67 8 729 740
329. Kantarci G., Eren Z., Demiraǧ A., Dogan I., Cakalagaoglu F., Yilmaz G. JC virus-associated nephropathy in a renal transplant recipient and comparative analysis of previous cases. Transpl Infect Dis: 2011; 13 1 89 92
330. Randhawa P., Baksh F., Aoki N., Tschirhart D., Finkelstein S. JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation: 2001; 71 9 1300 1303
331. Gardner S. D., MacKenzie E. F., Smith C., Porter A. A. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol: 1984; 37 5 578 586
332. Sahraian M. A., Radue E. W., Eshaghi A., Besliu S., Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol: 2012; 19 8 1060 1069
333. Khanna N., Elzi L., Mueller N. J., et al. Swiss HIV Cohort Study Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis: 2009; 48 10 1459 1466
334. Christensen K. L., Holman R. C., Hammett T. A., Belay E. D., Schonberger L. B. Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005. Neuroepidemiology: 2010; 35 3 178 184
335. Amend K. L., Turnbull B., Foskett N., Napalkov P., Kurth T., Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology: 2010; 75 15 1326 1332
336. García-Suárez J., de Miguel D., Krsnik I., Bañas H., Arribas I., Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol: 2005; 80 4 271 281
337. Carson K. R., Focosi D., Major E. O., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol: 2009; 10 8 816 824
338. Molloy E. S., Calabrese L. H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum: 2009; 60 12 3761 3765
339. Berger J. R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf: 2010; 33 11 969 983
340. Carson K. R., Evens A. M., Richey E. A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood: 2009; 113 20 4834 4840
341. Major E. O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med: 2010; 61 35 47
342. Tan I. L., McArthur J. C., Clifford D. B., Major E. O., Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology: 2011; 77 11 1061 1067
343. Clifford D. B., De Luca A., Simpson D. M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol: 2010; 9 4 438 446
344. Keene D. L., Legare C., Taylor E., Gallivan J., Cawthorn G. M., Vu D. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci: 2011; 38 4 565 571
345. Kothary N., Diak I. L., Brinker A., Bezabeh S., Avigan M., Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol: 2011; 65 3 546 551
346. Neff R. T., Hurst F. P., Falta E. M., et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation: 2008; 86 10 1474 1478
347. Shitrit D., Nirit L., Shiran S. I., et al. Progressive multifocal leukoencephalopathy in a lung transplant recipient. J Heart Lung Transplant: 2003; 22 8 946 950
348. Waggoner J., Martinu T., Palmer S. M. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant: 2009; 28 4 395 398
349. Drachenberg C. B., Hirsch H. H., Papadimitriou J. C., et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation: 2007; 84 3 323 330
350. Focosi D., Marco T., Kast R. E., Maggi F., Ceccherini-Nelli L., Petrini M. Progressive multifocal leukoencephalopathy: what's new? Neuroscientist: 2010; 16 3 308 323
351. Berenguer J., Miralles P., Arrizabalaga J., et al. GESIDA 11/99 Study Group Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis: 2003; 36 8 1047 1052
352. De Luca A., Ammassari A., Pezzotti P., et al. Gesida 9/99, IRINA, ACTG 363 Study Groups Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS: 2008; 22 14 1759 1767
353. Hall C. D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med: 1998; 338 19 1345 1351
354. Verma S., Cikurel K., Koralnik I. J., et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis: 2007; 196 5 709 711
355. Cettomai D., McArthur J. C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol: 2009; 66 2 255 258
356. Brickelmaier M., Lugovskoy A., Kartikeyan R., et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother: 2009; 53 5 1840 1849
357. Focosi D., Fazzi R., Montanaro D., Emdin M., Petrini M. Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res: 2007; 74 2 156 158
358. Buckanovich R. J., Liu G., Stricker C., et al. Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol: 2002; 81 7 410 413
359. Moenster R. P., Jett R. A. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm: 2012; 69 6 496 498
360. Henquell C., Boeuf B., Mirand A., et al. Fatal adenovirus infection in a neonate and transmission to health-care workers. J Clin Virol: 2009; 45 4 345 348
361. Lynch J. P. III, Fishbein M., Echavarria M. Adenovirus. Semin Respir Crit Care Med: 2011; 32 4 494 511
362. Lee J., Choi E. H., Lee H. J. Comprehensive serotyping and epidemiology of human adenovirus isolated from the respiratory tract of Korean children over 17 consecutive years (1991-2007). J Med Virol: 2010; 82 4 624 631
363. Kajon A. E., Lu X., Erdman D. D., et al. Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States. J Infect Dis: 2010; 202 1 93 103
364. Houng H. S., Gong H., Kajon A. E., et al. Genome sequences of human adenovirus 14 isolates from mild respiratory cases and a fatal pneumonia, isolated during 2006-2007 epidemics in North America. Respir Res: 2010; 11 116
365. Kajon A. E., Dickson L. M., Metzgar D., Houng H. S., Lee V., Tan B. H. Outbreak of febrile respiratory illness associated with adenovirus 11a infection in a Singapore military training cAMP. J Clin Microbiol: 2010; 48 4 1438 1441
366. Ison M. G. Adenovirus infections in transplant recipients. Clin Infect Dis: 2006; 43 3 331 339
367. Chang S. Y., Lee C. N., Lin P. H., et al. A community-derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005. J Med Virol: 2008; 80 1 102 112
368. Echavarría M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev: 2008; 21 4 704 715
369. Kim Y-J, Boeckh M., Englund J. A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med: 2007; 28 2 222 242
370. Yeung R., Eshaghi A., Lombos E., et al. Characterization of culture-positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada: September 2007-June 2008. Virol J: 2009; 6 11
371. Moura P. O., Roberto A. F., Hein N., et al. Molecular epidemiology of human adenovirus isolated from children hospitalized with acute respiratory infection in São Paulo, Brazil. J Med Virol: 2007; 79 2 174 181
372. Chen H. L., Chiou S. S., Hsiao H. P., et al. Respiratory adenoviral infections in children: a study of hospitalized cases in southern Taiwan in 2001-2002. J Trop Pediatr: 2004; 50 5 279 284
373. Russell K. L., Hawksworth A. W., Ryan M. A., et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine: 2006; 24 15 2835 2842
374. Zheng X., Lu X., Erdman D. D., et al. Identification of adenoviruses from high risk pediatric stem cell transplant recipients and controls. J Clin Microbiol: 2007; 46 1 317 320
375. Bil-Lula I., Ussowicz M., Rybka B., et al. Hematuria due to adenoviral infection in bone marrow transplant recipients. Transplant Proc: 2010; 42 9 3729 3734
376. Chemaly R. F., Ghosh S., Bodey G. P., et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore): 2006; 85 5 278 287
377. Lessa F. C., Gould P. L., Pascoe N., et al. Health care transmission of a newly emergent adenovirus serotype in health care personnel at a military hospital in Texas, 2007. J Infect Dis: 2009; 200 11 1759 1765
378. Russell K. L., Broderick M. P., Franklin S. E., et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting. J Infect Dis: 2006; 194 7 877 885
379. Leruez-Ville M., Chardin-Ouachée M., Neven B., et al. Description of an adenovirus A31 outbreak in a paediatric haematology unit. Bone Marrow Transplant: 2006; 38 1 23 28
380. Mattner F., Sykora K. W., Meissner B., Heim A. An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit: analysis of clinical impact and preventive strategies. Pediatr Infect Dis J: 2008; 27 5 419 424
381. Ishiko H., Aoki K. Spread of epidemic keratoconjunctivitis due to a novel serotype of human adenovirus in Japan. J Clin Microbiol: 2009; 47 8 2678 2679
382. Sdiri-Loulizi K., Gharbi-Khelifi H., de Rougemont A., et al. Molecular epidemiology of human astrovirus and adenovirus serotypes 40/41 strains related to acute diarrhea in Tunisian children. J Med Virol: 2009; 81 11 1895 1902
383. Hakim F. A., Tleyjeh I. M. Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature. Eur J Clin Microbiol Infect Dis: 2008; 27 2 153 158
384. Hamada N., Gotoh K., Hara K., et al. Nosocomial outbreak of epidemic keratoconjunctivitis accompanying environmental contamination with adenoviruses. J Hosp Infect: 2008; 68 3 262 268
385. Filho E. P., da Costa Faria N. R., Fialho A. M., et al. Adenoviruses associated with acute gastroenteritis in hospitalized and community children up to 5 years old in Rio de Janeiro and Salvador, Brazil. J Med Microbiol: 2007; 56 Pt 3 313 319
386. Symeonidis N., Jakubowski A., Pierre-Louis S., et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis: 2007; 9 2 108 113
387. Yokose N., Hirakawa T., Inokuchi K. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib. Leuk Res: 2009; 33 8 e106
388. Fanourgiakis P., Georgala A., Vekemans M., et al. Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis: 2005; 40 1 199 201
389. Ferreira G. F., Oliveira R. A., Lucon M., et al. Hemorrhagic cystitis secondary to adenovirus or herpes simplex virus infection following renal transplantation: four case reports. Transplant Proc: 2009; 41 10 4416 4419
390. Keswani M., Moudgil A. Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient. Pediatr Transplant: 2007; 11 5 568 571
391. Mori K., Yoshihara T., Nishimura Y., et al. Acute renal failure due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant: 2003; 31 12 1173 1176
392. Sujeet K., Vasudev B., Desai P., et al. Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient. Transpl Infect Dis: 2011; 13 2 174 177
393. Bruno B., Zager R. A., Boeckh M. J., et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation: 2004; 77 7 1049 1057
394. Bowles N. E., Ni J., Kearney D. L., et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol: 2003; 42 3 466 472
395. Gray G. C., McCarthy T., Lebeck M. G., et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis: 2007; 45 9 1120 1131
396. Melón S., Méndez S., Iglesias B., et al. Involvement of adenovirus in clinical mononucleosis-like syndromes in young children. Eur J Clin Microbiol Infect Dis: 2005; 24 5 314 318
397. Robin M., Marque-Juillet S., Scieux C., et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica: 2007; 92 9 1254 1257
398. Kroes A. C., de Klerk E. P., Lankester A. C., et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol: 2007; 38 4 341 347
399. de Mezerville M. H., Tellier R., Richardson S., Hébert D., Doyle J., Allen U. Adenoviral infections in pediatric transplant recipients: a hospital-based study. Pediatr Infect Dis J: 2006; 25 9 815 818
400. Sivaprakasam P., Carr T. F., Coussons M., et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol: 2007; 29 2 81 85
401. Neofytos D., Ojha A., Mookerjee B., et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant: 2007; 13 1 74 81
402. Erard V., Huang M. L., Ferrenberg J., et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis: 2007; 45 8 958 965
403. Sujeet K., Vasudev B., Desai P., et al. Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient. Transpl Infect Dis: 2011; 13 2 174 177
404. Humar A., Kumar D., Mazzulli T., et al. PV16000 Study Group A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant: 2005; 5 10 2555 2559
405. Moulik M., Breinholt J. P., Dreyer W. J., et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. J Am Coll Cardiol: 2010; 56 7 582 592
406. Shirali G. S., Ni J., Chinnock R. E., et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med: 2001; 344 20 1498 1503
407. Ohori N. P., Michaels M. G., Jaffe R., Williams P., Yousem S. A. Adenovirus pneumonia in lung transplant recipients. Hum Pathol: 1995; 26 10 1073 1079
408. Bridges N. D., Spray T. L., Collins M. H., Bowles N. E., Towbin J. A. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg: 1998; 116 4 617 623
409. Simsir A., Greenebaum E., Nuovo G., Schulman L. L. Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation: 1998; 65 4 592 594
410. Naesens L., Lenaerts L., Andrei G., et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother: 2005; 49 3 1010 1016
411. Yusuf U., Hale G. A., Carr J., et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation: 2006; 81 10 1398 1404
412. Doan M. L., Mallory G. B., Kaplan S. L., et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant: 2007; 26 9 883 889
413. Walls T., Hawrami K., Ushiro-Lumb I., Shingadia D., Saha V., Shankar A. G. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis: 2005; 40 9 1244 1249
414. Heemskerk B., Lankester A. C., van Vreeswijk T., et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis: 2005; 191 4 520 530
415. Sauerbrei A., Sehr K., Brandstädt A., Heim A., Reimer K., Wutzler P. Sensitivity of human adenoviruses to different groups of chemical biocides. J Hosp Infect: 2004; 57 1 59 66
416. Trei J. S., Johns N. M., Garner J. L., et al. Spread of adenovirus to geographically dispersed military installations, May-October 2007. Emerg Infect Dis: 2010; 16 5 769 775